Blog / Archives
Vermillion(VRML):Novel Diagnostic Tests Utilizing Biomarkers
Restructuring Play in Diagnostics at a VC Valuation Vermilion(VRML) technology utilizes a panel of biomarkers integrated with multivariate analysis software to develop disease specific assays. The...
Rayno Life Science Portfolio:Gen-Probe(GPRO) Files PMA Application for HPV
Gen-Probe (GPRO,$51.60) announced yesterday that it submitted a Premarket Approval Application(PMA) the the FDA for its APTIMA HPV (human papillomavirus ) assay , a molecular diagnostic test that...
Cepheid (CPHD) GeneXpert TB Test in India
"A Deadly Misdiagnosis" by Michael Specter An interesting article in the November 15 New Yorker on the Tuberculosis epidemic in India stresses the need for more accurate diagnostic tests and how the...
Biomarkers and Blood Screening Tests: GenProbe (GPRO) and Genzyme(GENZ)
Here are some relevant news in areas that we previously covered: Biomarkers Genzyme (GENZ) licensed a lung cancer test under development to Roche and can target a patient's response to their Tarceva...
Market Ignores Bad News, Rallies on Retail Outlook
The market overcame bad news for Ireland and European debt, insider trading investigations , Korean crisis and a weak housing market for an S&P rally of 1.49%. NASDAQ is doing even better up...
Rayno Life Science Portfolio: Regeneron(REGN)up 14% on Eye Drug Phase 3 Results
Regeneron(REGN $28) stock soared today on two parallel Phase 3 studies with patients who had neovascular age related macular degeneration(wet AMD), the VEGF Trap Eye drug successfully met the...
Rayno Life Science Portfolio:Exelixis (EXEL) and Neogen (NEOG) Soar
Exelixis (EXEL) stock was up over 30% today to $6.14 on positive data from two experimental cancer drugs for prostate and ovarian cancer. The XL 184 drug showed promising results with...
Rayno SnowBlog: LaNina Advisory-Nat Gas Up on Cold Weather- Update
11/23/10 Nat Gas is approaching its mid-Sep highs as cold weather is forecasted to continue for the next 10-14 days. Today's high is $4.29 up from lows around $3.70 on Oct 25. The Jan.'11 Futures...
Microfluidics (MFLU.OB) Revenues Down 9% but Value Play Intact
Microfluidics reported revenues of $4.1M for Q3 2010 ended Sep 30 a decrease of 9% or $500k compared to the same period of 2009. Excluding revenues of $1.3M attributed to machine production of the...
Rayno Life Science Portfolio Update: BLUD,ILMN, NEOG,SQNM
Immucor (BLUD) stock was up 5.7% to $18.91 on news that the DOJ closed its anti-trust investigation. The stock hit a low in early October when it slashed guidance due to lower utility of blood...